{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:28:23Z","timestamp":1791340103486,"version":"4.3.1"},"reference-count":35,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,1,21]]},"abstract":"<jats:title>Key Points<\/jats:title>\n                  <jats:p>Activating mutations outside exon 10 of MPL were identified in 10% (7 of 69) of triple-negative cases of ET and PMF. JAK2-V625F and JAK2-F556V were identified in 2 triple-negative cases of ET and were shown to activate JAK-STAT5 signaling.<\/jats:p>","DOI":"10.1182\/blood-2015-07-661835","type":"journal-article","created":{"date-parts":[[2015,9,30]],"date-time":"2015-09-30T23:15:02Z","timestamp":1443654902000},"page":"325-332","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":274,"title":["Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms"],"prefix":"10.1182","volume":"127","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7420-3298","authenticated-orcid":false,"given":"Jelena D.","family":"Milosevic Feenstra","sequence":"first","affiliation":[{"name":"CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harini","family":"Nivarthi","sequence":"additional","affiliation":[{"name":"CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0295-7629","authenticated-orcid":false,"given":"Heinz","family":"Gisslinger","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Hematology and Blood Coagulation, Medical University of Vienna, Vienna, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Leroy","sequence":"additional","affiliation":[{"name":"Ludwig Institute for Cancer Research, Brussels, Belgium;"},{"name":"de Duve Institute, Universit\u00e9 Catholique de Louvain, Brussels, Belgium;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Rumi","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilyas","family":"Chachoua","sequence":"additional","affiliation":[{"name":"Ludwig Institute for Cancer Research, Brussels, Belgium;"},{"name":"de Duve Institute, Universit\u00e9 Catholique de Louvain, Brussels, Belgium;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaudia","family":"Bagienski","sequence":"additional","affiliation":[{"name":"CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanka","family":"Kubesova","sequence":"additional","affiliation":[{"name":"CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria;"},{"name":"Center of Molecular Biology and Gene Therapy, Department of Internal Medicine\u2013Hematology and Oncology, University Hospital Brno and Medical Faculty Masaryk University, Brno, Czech Republic; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Pietra","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina","family":"Gisslinger","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Hematology and Blood Coagulation, Medical University of Vienna, Vienna, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Milanesi","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"J\u00e4ger","sequence":"additional","affiliation":[{"name":"CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris","family":"Chen","sequence":"additional","affiliation":[{"name":"CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiina","family":"Berg","sequence":"additional","affiliation":[{"name":"CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schalling","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Hematology and Blood Coagulation, Medical University of Vienna, Vienna, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schuster","sequence":"additional","affiliation":[{"name":"CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Bock","sequence":"additional","affiliation":[{"name":"CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan N.","family":"Constantinescu","sequence":"additional","affiliation":[{"name":"Ludwig Institute for Cancer Research, Brussels, Belgium;"},{"name":"de Duve Institute, Universit\u00e9 Catholique de Louvain, Brussels, Belgium;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6984-8817","authenticated-orcid":false,"given":"Mario","family":"Cazzola","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy;"},{"name":"Department of Molecular Medicine, University of Pavia, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Kralovics","sequence":"additional","affiliation":[{"name":"CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria;"},{"name":"Department of Internal Medicine I, Division of Hematology and Blood Coagulation, Medical University of Vienna, Vienna, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"9464","key":"2019111902093472200_B1","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"issue":"7037","key":"2019111902093472200_B2","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"issue":"17","key":"2019111902093472200_B3","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders.","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111902093472200_B4","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"issue":"7","key":"2019111902093472200_B5","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1182\/blood-2012-12-473777","article-title":"A novel activating, germline JAK2 mutation, JAK2R564Q, causes familial essential thrombocytosis.","volume":"123","author":"Etheridge","year":"2014","journal-title":"Blood"},{"issue":"10","key":"2019111902093472200_B6","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1056\/NEJMc1200349","article-title":"Germline JAK2 mutation in a family with hereditary thrombocytosis.","volume":"366","author":"Mead","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111902093472200_B7","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/ajh.23614","article-title":"A novel germline JAK2 mutation in familial myeloproliferative neoplasms.","volume":"89","author":"Rumi","year":"2014","journal-title":"Am J Hematol"},{"issue":"25","key":"2019111902093472200_B8","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms.","volume":"369","author":"Klampfl","year":"2013","journal-title":"N Engl J Med"},{"issue":"25","key":"2019111902093472200_B9","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.","volume":"369","author":"Nangalia","year":"2013","journal-title":"N Engl J Med"},{"issue":"7","key":"2019111902093472200_B10","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med"},{"issue":"10","key":"2019111902093472200_B11","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients.","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"issue":"1","key":"2019111902093472200_B12","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1182\/blood-2008-01-131664","article-title":"MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.","volume":"112","author":"Beer","year":"2008","journal-title":"Blood"},{"issue":"5","key":"2019111902093472200_B13","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1182\/blood-2005-06-2600","article-title":"An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor.","volume":"107","author":"Staerk","year":"2006","journal-title":"Blood"},{"issue":"11","key":"2019111902093472200_B14","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1182\/blood-2003-10-3471","article-title":"Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin.","volume":"103","author":"Ding","year":"2004","journal-title":"Blood"},{"issue":"2","key":"2019111902093472200_B15","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1158\/0008-5472.CAN-09-3783","article-title":"Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.","volume":"70","author":"Abdel-Wahab","year":"2010","journal-title":"Cancer Res"},{"issue":"22","key":"2019111902093472200_B16","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","article-title":"Mutation in TET2 in myeloid cancers.","volume":"360","author":"Delhommeau","year":"2009","journal-title":"N Engl J Med"},{"issue":"24","key":"2019111902093472200_B17","doi-asserted-by":"crossref","first-page":"6182","DOI":"10.1182\/blood-2008-12-194548","article-title":"Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms.","volume":"113","author":"Grand","year":"2009","journal-title":"Blood"},{"issue":"19","key":"2019111902093472200_B18","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1182\/blood-2011-11-390252","article-title":"Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome.","volume":"119","author":"Zhang","year":"2012","journal-title":"Blood"},{"key":"2019111902093472200_B19","article-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues.","author":"Swerdlow","year":"2008"},{"issue":"5","key":"2019111902093472200_B20","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"issue":"11","key":"2019111902093472200_B21","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/ajh.23309","article-title":"Clinical significance of genetic aberrations in secondary acute myeloid leukemia.","volume":"87","author":"Milosevic","year":"2012","journal-title":"Am J Hematol"},{"issue":"17","key":"2019111902093472200_B22","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1182\/blood-2009-05-222331","article-title":"Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis.","volume":"114","author":"Malcovati","year":"2009","journal-title":"Blood"},{"issue":"7","key":"2019111902093472200_B23","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1073\/pnas.1211560110","article-title":"Tryptophan at the transmembrane-cytosolic junction modulates thrombopoietin receptor dimerization and activation.","volume":"110","author":"Defour","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"2019111902093472200_B24","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/j.exphem.2008.06.006","article-title":"Genetic profiling of myeloproliferative disorders by single-nucleotide polymorphism oligonucleotide microarray.","volume":"36","author":"Kawamata","year":"2008","journal-title":"Exp Hematol"},{"issue":"11","key":"2019111902093472200_B25","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/j.exphem.2007.08.010","article-title":"Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis.","volume":"35","author":"Williams","year":"2007","journal-title":"Exp Hematol"},{"issue":"6","key":"2019111902093472200_B26","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1182\/blood-2008-01-134049","article-title":"YRRL motifs in the cytoplasmic domain of the thrombopoietin receptor regulate receptor internalization and degradation.","volume":"112","author":"Hitchcock","year":"2008","journal-title":"Blood"},{"issue":"5","key":"2019111902093472200_B27","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.hoc.2012.07.005","article-title":"Role of germline genetic factors in MPN pathogenesis.","volume":"26","author":"Harutyunyan","year":"2012","journal-title":"Hematol Oncol Clin North Am"},{"issue":"5","key":"2019111902093472200_B28","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/ajh.23138","article-title":"A novel mutation in MPL (Y252H) results in increased thrombopoietin sensitivity in essential thrombocythemia.","volume":"87","author":"Lambert","year":"2012","journal-title":"Am J Hematol"},{"issue":"2","key":"2019111902093472200_B29","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1365-2141.2008.07430.x","article-title":"Familial thrombocytosis caused by the novel germ-line mutation p.Pro106Leu in the MPL gene.","volume":"144","author":"El-Harith","year":"2009","journal-title":"Br J Haematol"},{"issue":"7","key":"2019111902093472200_B30","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1073\/pnas.0308530100","article-title":"Structure of the receptor-binding domain of human thrombopoietin determined by complexation with a neutralizing antibody fragment.","volume":"101","author":"Feese","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"issue":"34","key":"2019111902093472200_B31","doi-asserted-by":"crossref","first-page":"26697","DOI":"10.1074\/jbc.M110.120956","article-title":"Identification of the residues in the extracellular domain of thrombopoietin receptor involved in the binding of thrombopoietin and a nuclear distribution protein (human NUDC).","volume":"285","author":"Chen","year":"2010","journal-title":"J Biol Chem"},{"issue":"7","key":"2019111902093472200_B32","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/leu.2014.3","article-title":"CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons.","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"issue":"21","key":"2019111902093472200_B33","doi-asserted-by":"crossref","first-page":"5585","DOI":"10.1182\/blood.V124.21.5585.5585","article-title":"Familiar JAK2 G571S variant not linked with essential trombocythemia [abstract].","volume":"124","author":"Panovska-Stavridis","year":"2014","journal-title":"Blood"},{"issue":"21","key":"2019111902093472200_B34","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.4589.4589","article-title":"Genomic profile of patients with triple negative (JAK2, CALR and MPL) essential thrombocythemia and primary myelofibrosis [abstract].","volume":"124","author":"Campregher","year":"2014","journal-title":"Blood"},{"key":"2019111902093472200_B35","article-title":"Mutational profile in essential thrombocytemia (Et) \u201cnegative\u201d for Jak2 and Mpl [abstract].","author":"Cabagnols","journal-title":"Haematologica"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/127\/3\/325\/1393686\/325.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/127\/3\/325\/1393686\/325.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T02:09:46Z","timestamp":1574129386000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/127\/3\/325\/34897\/Wholeexome-sequencing-identifies-novel-MPL-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,21]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,1,21]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2015-07-661835","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,21]]}}}